Divis Laboratories
Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Divis Laboratories's score of 38 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Divis Laboratories's reported carbon emissions
In 2024, Divis Laboratories, headquartered in India, reported significant carbon emissions, with Scope 1 emissions totalling approximately 363,246,000 kg CO2e and Scope 2 emissions at about 325,972,000 kg CO2e. This reflects a decrease from 2023, where Scope 1 emissions were around 380,676,000 kg CO2e and Scope 2 emissions were approximately 373,141,000 kg CO2e. The company has committed to reducing its greenhouse gas emissions intensity by 25% for both Scope 1 and Scope 2 by 2030, starting from 2023. Divis Laboratories has also set long-term net-zero commitments across all scopes, aiming for a comprehensive reduction strategy by 2050. The company is actively working towards these targets, demonstrating a commitment to sustainability within the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 380,676,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 373,141,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Divis Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
